The Only Industry-Led Forum, Focused on HER2
as a Pan-Tumor Target
HER2 Targeted Therapies strives to create a community dedicated to optimizing the next generation of anti-HER2 drugs and to maximize the clinical utility of HER2 as a pan-tumor target.
New this year, the HER2-Targeted Therapies Summit is comprehensively addressing the industry’s key challenges of optimizing novel anti-HER2 drugs and exploring how to expand the clinical utility of HER2 across breast, colorectal, lung, endometrial tumors & more!
With continued challenges of drug resistance, suboptimal duration of response and disease relapse associated with existing anti-HER2 drugs, the growing clinical need for HER2 expressing patients requires next generation HER2-targeted therapies. This meeting will be the centerpoint for exploring all HER2-targeting drug classes, including: antibody drug conjugates, bispecifics, TKIs, CAR approaches & more!
From HER2 quantitative pathology to HER2 heterogeneity in diseases beyond breast cancer and blood brain barrier penetrable anti-HER2 approaches, this conference will delve into challenges that have obstructed the expansion of HER2 as a pan-tumor target.
Alongside your peers you have the opportunity to hear from and interact with 24+ thought leaders in our expert speaker faculty, have access to 18+ hours of content exploring the latest advances in the HER2-targeted therapy field, form meaningful and long-lasting connections in the multiple and varied hybrid networking sessions built into the event.